Navigation Links
Mayo Clinic: New multiple myeloma treatment guidelines personalize therapy for patients
Date:4/1/2013

ROCHESTER, Minn. -- Researchers at Mayo Clinic Cancer Center have developed new guidelines to treat recently diagnosed multiple myeloma patients who are not participating in clinical trials. The guidelines give physicians practical, easy to follow recommendations for providing initial therapy, stem cell transplant and maintenance therapy. The guidelines are published in the current issue of the journal Mayo Clinic Proceedings and represent a consensus opinion of hematologists at Mayo Clinic Cancer Center sites in Minnesota, Florida and Arizona.

"Multiple myeloma is an incurable blood cancer that affects more than 20,000 people in the U.S. each year," says lead author Joseph Mikhael, M.D. a hematologist at Mayo Clinic in Arizona. "Over the past decade we have made great progress in understanding the disease, developing drug therapies and increasing overall survival. However, as a medical community we haven't done as good a job at optimizing therapy based on a patient's individual risk factors."

Dr. Mikhael says the new guidelines will help patients with low-risk disease avoid the harsh side effects of therapy and will reserve more intense therapy for patients with aggressive disease.

Among the guidelines:

  • A strong recommendation to enroll patients in clinical trials as the first option for therapy or supportive care.

  • Separating patients by risk into three groups to make the most of new drug therapy: high risk, intermediate risk and low risk. Previous guidelines included only two groups: high risk and standard risk.

  • Adding factors to assess the risk the multiple myeloma poses to the patient, including use of gene expression profiling to help identify patients with high-risk disease.

  • Greater emphasis on delaying stem cell transplants to take advantage of improved chemotherapy, resulting in better responses.

  • Maintenance therapy using drugs such as lenalidomide and bortezomib that balance benefit with short- and long-term toxicity.


'/>"/>

Contact: Joe Dangor
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. Mayo Clinic: Skin problems, joint disorders top list of reasons people visit doctors
2. Mayo Clinic: 2-drug combination may slow deadly thyroid cancer
3. Mayo Clinic: Less invasive surgery detects residual breast cancer in lymph nodes after chemotherapy
4. Mayo Clinic: Antidepressant eases radiation-related mouth pain in head, neck cancer
5. Mayo Clinic: Diabetes can be controlled in patients after pancreas removal
6. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
7. Mayo Clinic: Common blood pressure drug linked to severe GI problems
8. Mayo Clinic: Molecule thought cancer foe actually helps thyroid tumors grow
9. Mayo Clinic: Standard heart disease risk tools underrate danger in rheumatoid arthritis
10. Mayo Clinic: Exhaustion renders immune cells less effective in cancer treatment
11. Mayo Clinic: Obesity epidemic fueling rise in rheumatoid arthritis among women
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... ... 2017 , ... Anesthesia Progress – Everyone wants less pain during ... option for each patient. Dentists have several general anesthesia alternatives and finding the right ... the Tokyo Dental College in Tokyo, Japan wanted to find out which anesthetic was ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... Healthful-Flex. , The company, owned and operated by Ed Stroup, was created ... reasonable price with the highest level of customer service. Healthful Balance products can ...
(Date:1/17/2017)... Clemente, CA (PRWEB) , ... January 17, 2017 ... ... Diego County, as well as Palm Desert, is opening a new office in ... Brainsway deep transcranial magnetic stimulation (dTMS) in Southern California, successfully treating individuals struggling ...
(Date:1/17/2017)... ... 2017 , ... A prescription medication bottle, pocket knife, luggage and a solar-powered ... Product Design Challenge , the Cradle to Cradle Products Innovation Institute has ... scheduled to run through early 2018. The challenges are presented by the Institute in ...
(Date:1/17/2017)... CA (PRWEB) , ... January 17, 2017 , ... Livionex, ... the results of a double blind clinical study for its dental gel that shows ... leading national brand of toothpaste containing triclosan. The study was conducted at the Beckman ...
Breaking Medicine News(10 mins):
(Date:1/17/2017)... 17, 2017  Zimmer Biomet Holdings, Inc. (NYSE and ... today announced that it has implemented a ... the Zimmer Biomet management team. Effective January 23, ... the position of President, Americas and join the ... served as Zimmer Biomet,s Vice President of U.S. ...
(Date:1/17/2017)... Research and Markets has announced the addition of the ... ... laparotomy sponges market to grow at a CAGR of 7.94% during ... 2016-2020, has been prepared based on an in-depth market analysis with ... its growth prospects over the coming years. The report also includes ...
(Date:1/17/2017)... BELLEFONTE, Pa. , Jan. 17, 2017 /PRNewswire/ ... Medical, Inc.(AMI) announces the addition of 6 senior ... of the TubeClear® System.  These sales leaders were ... recently acquired medical device company. Repeatedly recognized for ... of exceeding customer expectations and establishing relationships with ...
Breaking Medicine Technology: